PT - JOURNAL ARTICLE AU - Auriel A. Willette AU - Colleen Pappas AU - Nathan Hoth AU - Qian Wang AU - Brandon Klinedinst AU - Sara A. Willette AU - Brittany Larsen AU - Amy Pollpeter AU - Tianqi Li AU - Scott Le AU - Jonathan P. Mochel AU - Karin Allenspach AU - Robert Dantzer AU - and for the Alzheimer’s disease Neuroimaging Initiative TI - Neuroinflammation, Depressive Affect, and Amyloid Burden in Alzheimer’s Disease: Insights from the Kynurenine Pathway AID - 10.1101/2020.08.11.20172940 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.11.20172940 4099 - http://medrxiv.org/content/early/2020/08/14/2020.08.11.20172940.short 4100 - http://medrxiv.org/content/early/2020/08/14/2020.08.11.20172940.full AB - Background Depressive symptoms in Alzheimer’s disease (AD) predict worse cognitive and functional outcomes. Both AD and major depression are characterized by shunted tryptophan metabolism away from serotonin (5-HT) and toward the neuroinflammatory kynurenine (Kyn) pathway. The present study assessed the role of Kyn across the AD continuum in behavioral, neuroanatomical, neuropathological, and physiological outcomes.Methods In 746 participants from the Alzheimer’s Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter.Results A higher Kyn/Tryptophan ratio was linked to many inflammatory markers, as well as lower functional independence and memory scores. A higher Kyn/5-HT ratio showed similar associations, but also strong relationships with depressive affect and neuropsychiatric disturbance, executive dysfunction, and global cognitive decline. Further, gray matter atrophy was seen in hippocampus, anterior cingulate, and prefrontal cortices, as wel as greater amyloid and total tau deposition. Finally, using moderated-mediation, several pro-inflammatory factors partially mediated Kyn/5-HT and depressive affect scores in participants with subclinical Aβ (i.e., Aβ-), whereas such associations were fully mediated by Complement 3 in Aβ+ participants.Conclusions These findings suggest that neuroinflammatory signaling cascades may occur during AD, resulting in increased Kyn metabolism that influences the pathogenesis of depressive symptoms. Aβ and the complement system may be critical contributing factors in this process.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by the College of Human Sciences at Iowa State University, a Big Data Brain Initiative grant through the Iowa State University Office of Vice President for Research, NIH grant AG047282, and the Alzheimer's Association Research Grant to Promote Diversity grant AARGD-17-529552. No funding source had any involvement in the report. Data collection and sharing for this project were funded by the ADNI (National Institutes of Health Grant U01-AG-024904) and Department of Defense ADNI (award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This report used deidentified secondary data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). This research is therefore exempt from local IRB oversight. Written informed consent was obtained from all ADNI participants at their respective sites. Site-specific Institutional Review Boards approved the ADNI protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was downloaded and is accessible to bona fide researchers. Data access instructions are available in the hyperlink we note below. http://adni.loni.usc.edu/data-samples/access-data/